We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OXIG Oxford Instruments Plc

15.00 (0.58%)
12 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Instruments Plc LSE:OXIG London Ordinary Share GB0006650450 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  15.00 0.58% 2,585.00 2,585.00 2,595.00 2,600.00 2,570.00 2,580.00 39,926 16:35:10
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Lab Analytical Instruments 470.4M 50.7M 0.8753 29.65 1.49B
Oxford Instruments Plc is listed in the Lab Analytical Instruments sector of the London Stock Exchange with ticker OXIG. The last closing price for Oxford Instruments was 2,570p. Over the last year, Oxford Instruments shares have traded in a share price range of 1,634.00p to 2,765.00p.

Oxford Instruments currently has 57,920,505 shares in issue. The market capitalisation of Oxford Instruments is £1.49 billion. Oxford Instruments has a price to earnings ratio (PE ratio) of 29.65.

Oxford Instruments Share Discussion Threads

Showing 526 to 549 of 900 messages
Chat Pages: Latest  24  23  22  21  20  19  18  17  16  15  14  13  Older
what % of revenue does Russia account for ??

Arrgh down £3.
22 January 2015

Release date: 7am 22(nd) January 2015

Oxford Instruments plc Quarter 3 Trading Update

22 January 2015

Oxford Instruments plc, a leading provider of high technology tools and systems for industry and research, today issues a Quarter 3 Trading Update which covers the period from 1st October 2014 to date.

In the third quarter organic orders and revenues were similar to the same period last year. In addition, Andor the acquisition made in the fourth quarter last year continues to perform well.

Significant orders, both taken in the year and forecast to be taken in Quarter 4, are for delivery to Russia. Recent tightening in the application of trade sanctions and, in particular the cancelling of certain export licences mean we no longer expect to convert theses orders to sales. We now assume that no sales can be made to Russia for the remainder of this year and we are also assuming no sales to Russia next year.

In addition, our forecast of recovery in the Japanese market has not yet occurred. The effects of Russia and Japan, combined with weaker trading in our short lead-time Industrial Analysis business means that, whilst we expect revenues for the second half to be ahead of the same period last year, we believe they will fall short of market expectations. We now anticipate adjusted profit before tax for the current year will be approximately GBP35 million.

In response to these challenges we are taking action to reduce costs and improve efficiency. Subject to consultation this may result in the closure of some sites and a reduction in headcount. This project aims to produce a cost saving of GBP6 million in the next financial year. The one off, cash costs of achieving these savings are expected to be in the region of GBP5 million which will be taken as an exceptional item in the current year.

Whilst it is not possible to predict when the situation in Russia will recover, order intake in Japan is improving. We expect to see the Group grow next year and beyond as we execute on our nanotechnology strategy.


A quick look looks like a classic market overreaction to me , so in cavalier fashion just added a lump at 808.

wad collector
trading update worse than I expected:

In addition, our forecast of recovery in the Japanese market has not yet occurred. The effects of Russia and Japan, combined with weaker trading in our short lead-time Industrial Analysis business means that, whilst we expect revenues for the second half to be ahead of the same period last year, we believe they will fall short of market expectations. We now anticipate adjusted profit before tax for the current year will be approximately £35 million.

back of envelope calculation suggest eps will be around 47p so currently on p/e of about 17.4. Still looks overvalued in the short term IMO.

alter ego
Someone's interested. Fascinating co that would make a useful target for someone such as GE?
small crow
Thanks for your thoughts, Alter. Thought had a bit more in it, but hard to tell.
tratante, I may not be totally objective here as I recently sold my holding believing OXIG to be overvalued. However, looking at the forecast for year end 3/15, it shows expected eps of 61.7p and at around 1200p the p/e is still 19.5 - hardly good value for a stock that is expected to show a fall in earnings this year and lacking much of a dividend yield to support the share price

Given the general market it's not surprising to me that the share price is showing signs of weakness.

alter ego
No, but familiar daily pattern...
small crow
Anyone know any material reason why this is falling back today?
Not quite!
wad collector
Promising run again this week ; will it touch £13 before the year is out?
wad collector
Potential for INV H&S.
Agree ; hate watching paper gains drift away untapped..
wad collector
wad collector - also tempted but succumbed. Will aim to buy again if/when share price drifts down as it appears inclined to do. Not my normal style but short term outlook isn't exciting and a profit is a profit.
alter ego
Up 5% today on no visible OXIG-specific news , tempted to take a 2 month 33% profit .The narrow spread is appealing to the trader in me , but I am going to sit on hands for now ; this is a quality company in a good niche. The yield is low but well covered.
wad collector
Strange patterns of trades in this stock. Anyone know what might be happening?
small crow
A flurry of broker adjustments , FWIW.

Liberum , Beayfort and Berenberg still say Buy but reduced targets to 1200 and 1360. JPM overweight but target down to 1360 .
Numis say add to 1350 , Singer Hold to 1350
Investec are thinking about it .

I don't why I am posting this really , they would appear to be guessing...

wad collector
The quick 10% has come , but I think I will go for the slow 50% instead...
wad collector
Well , 940 was too much for me to resist . Have patiently watched these since I sold a couple of years ago. More speculative than most of my holdings but a good chance of a quick 10% I suspect...or a slow 50% .
wad collector
I am looking to buy OXIG once it successfully holds above £10.50p
I asked the kind gent that is dasv on the SHA thread to have look at their underlying metrics for me and this is what he found. It is NOT pretty!
Followed by my reply.


dasv 3 Oct'14 - 07:36 - 34568 of 34580

c2i: OXIG

ROCE too low for me: 6.8% (I like 12%+)

Free cash flow and operating cash flow lower than EPS. Big difference between reported and normalised EPS - what's that about?

32m cash but 124m debt of all of a sudden? Debt is forecast to increase into 2016

Altman z1-score is 2.33 - Caution

EPS growth forecast -6.76% forecast.

2016E forecast +14.3% with a PEG of 0.85 so a turnaround by then?

Pays a divi - can it continue to do so with this cash/debt situation?

Brokers habe been lowering forecasts consistently over the last 12 months but retain a "buy" rating.


I haven't looked at the story on OXIG for a while. I'd be interested to hear what are your thoughts on why it's a long from here?


contrarian2investor 3 Oct'14 - 09:25 - 34579 of 34581 0 0 edit

Good morning dasv,

Thank you for taking the time to find those metrics for OXIG, very much appreciated.

Here are some of my reasons for looking at OXIG:

The area of nanotechnology (and graphene) could be growth drivers and OXIG could eventually be one of those winners.
The integration of ANDOR (with its high performance optical cameras and software which are used in both the physical and bio sciences) at some point could be significant drivers for growth.
Currency headwinds are now working in their favour.
Order book appears robust
Their new X-MET8000 handheld (X-ray fluorescence) XRF analyser should fly off the shelves.
A potential turnaround candidate, with the outlier being that it becomes a bolt-on target for a larger peer.
Henderson Global Investors increased its stake in OXIG to 5.45% on 26th September

OXIG Back on my radar.
Director moving shares into pension fund over on GWMO now so it was a good call for those who put OXIG profits over there
Profits from OXIG going into GWMO
I wish I could. I thought this was supposed to be a growth stock; certainly not an income one. Haven't seen any press/broker comment. Anyone?
Can anyone make sense of this. All over the shop.
Chat Pages: Latest  24  23  22  21  20  19  18  17  16  15  14  13  Older

Your Recent History

Delayed Upgrade Clock